Evidence map›Paper›PMID 32635292›Full record

ArticleJournal of clinical medicine2020

Child-Adult Transition in Sarcoidosis: A Series of 52 Patients.

Simon Chauveau, Florence Jeny, Marie-Emeline Montagne, Rola Abou Taam, Véronique Houdouin, Ulrich Meinzer, Christophe Delacourt, Ralph Epaud, Fleur Cohen Aubart, Catherine Chapelon-Abric and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Simon ChauveauAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Florence JenyAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Marie-Emeline MontagneAP-HP Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Armand Trousseau Hospital, 75012 Paris, France.
Rola Abou TaamAP-HP Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Necker Enfants Malades Hospital, 75015 Paris, France.
Véronique HoudouinAP-HP Pediatric Pulmonology Department, Robert Debré Hospital, 75019 Paris, France.
Ulrich MeinzerAP-HP Department of General Pediatrics, Pediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Center for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-Immune Diseases RAISE, Robert Debré University Hospital, 75019 Paris, France.
Christophe DelacourtAP-HP Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Necker Enfants Malades Hospital, 75015 Paris, France.
Ralph EpaudPediatric Department and Reference Center for Rare Lung Diseases (RespiRare), Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France.
Fleur Cohen AubartService de Médecine Interne 2, French National Reference Center for rare Systemic diseases, Hôpital de la Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Sorbonne Université, 75013-Paris, France.
Catherine Chapelon-AbricAP-HP Department of Internal Medicine and Clinical Immunology, La Pitié Salpétrière Hospital, AP-HP, 75013 Paris, France.
Dominique Israël-BietAP-HP Pulmonology Department, HEGP Hospital, 75015 Paris, France.
Karine JuvinAP-HP Pulmonology Department, HEGP Hospital, 75015 Paris, France.
Antoine DossierAP-HP Department of Internal Medicine, Bichat Hospital, 75018 Paris, France.
Bahram BodaghiAP-HP Department of Ophtalmology, La Pitié Salpétrière Hospital, IHU FOReSIGHT, Sorbonne Université, 75013 Paris, France.
Grégoire PrévotPulmonology Department, Larrey University Hospital, 31400 Toulouse, France.
Jean-Marc NaccacheAP-HP Pulmonology Department, Tenon Hospital, 75020 Paris, France.
Sarah MattioniAP-HP Department of Internal Medicine, Tenon Hospital, 75020 Paris, France.
Antoine DeschildreUniv. Lille, CHU Lille, Paediatric Pulmonology and Allergy Unit, Hôpital Jeanne de Flandre, F-59000 Lille, France.
Jacques BrouardPediatric Pulmonology Department, Caen University Hospital, 14000 Caen, France.
Abdellatif TaziAP-HP Pulmonology Department, Saint Louis Hospital, 75010 Paris, France.
Roderich MeckenstockInternal Medicine and Infectious Diseases Department, Versailles Hospital, 78150 Le Chesnay, France.
Morgane DidierAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Julien HarocheService de Médecine Interne 2, French National Reference Center for rare Systemic diseases, Hôpital de la Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Sorbonne Université, 75013-Paris, France.
Annick ClementAP-HP Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Armand Trousseau Hospital, 75012 Paris, France.
Jean-François BernaudinAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Hilario NunesAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Dominique ValeyreAP-HP Pulmonology Department, Avicenne Hospital, 93000 Bobigny, France.
Nadia NathanAP-HP Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Armand Trousseau Hospital, 75012 Paris, France.
For The French Sarcoidosis Group Gsf

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoidosis (≤15-year-old) who completed at least a three-year follow-up in French expert centers were included. Clinical information at presentation and outcome in adulthood were studied. (3) Results: A total of 52 patients were included (34 prospectively in childhood and 18 retrospectively in adulthood), with a mean age of 12 (±2.7) at diagnosis. The median duration time of follow-up was 11.5 years (range 3-44.5). Relapses mostly occurred during treatment decrease (84.5%), others within the three years after treatment interruption (9.1%), and rarely when the disease was stable for more than three years (6.4%). Sarcoidosis was severe in 11 (21.2%) in adulthood. Patients received a high corticosteroid cumulative dose (median 17,900 mg) for a median duration of five years (range 0-32), resulting in mostly mild (18; 35.3%) and rarely severe (2; 3.8%) adverse events. (4) Conclusions: Pediatric-onset sarcoidosis needed a long-term treatment in almost half of the patients. Around one fifth of pediatric-onset sarcoidosis patients had severe sarcoidosis consequences in adulthood.

Indexed as

childreninterstitial lung diseasesarcoidosistransition of care

Identifiers

PMID32635292
PMCPMC7408766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.